MK-7262

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HealthyLipoprotein(a)

Phase 1

A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

RecruitingNCT07619443

Merck Sharp & Dohme LLCHealthy

Start: 2026-07-01End: 2026-09-12Target: 30Updated: 2026-07-13

Phase 2

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

RecruitingNCT07614984

Merck Sharp & Dohme LLCLipoprotein(a)

Start: 2026-06-30End: 2027-10-12Target: 750Updated: 2026-07-20